FDA Boxed Warning Removal on Menopause Hormone Therapy: What Geriatricians Should Know

Area of Science:

• Geriatric Medicine
• Endocrinology
• Women's Health

Background:

• The FDA previously issued a boxed warning for hormone therapy (HT).
• This warning impacted prescribing practices and patient access to HT.
• Recent FDA actions have removed this boxed warning, signaling a shift.

Purpose of the Study:

• To review the implications of the FDA boxed warning removal for menopause hormone therapy.
• To provide key considerations for geriatricians managing older adults on HT.
• To guide evidence-based prescribing in the post-boxed warning era.

Main Methods:

• Review of FDA communications and policy changes regarding HT.
• Synthesis of current evidence on the risks and benefits of HT in older women.
• Analysis of clinical guidelines and expert recommendations.

Main Results:

• The removal of the boxed warning reflects updated understanding of HT risks and benefits.
• Geriatricians need to re-evaluate HT use based on individual patient profiles.
• Shared decision-making is crucial for safe and effective HT management.

Conclusions:

• The post-boxed warning era necessitates a nuanced approach to menopause hormone therapy.
• Geriatricians play a vital role in optimizing HT for older women.
• Focus should be on personalized treatment strategies and ongoing risk-benefit assessment.